Impel Neuropharma patents expiration

1. Trudhesa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550036 IMPEL NEUROPHARMA Nasal drug delivery device
Sep, 2032

(8 years from now)

US10507295 IMPEL NEUROPHARMA Nasal drug delivery device
Dec, 2032

(9 years from now)

US10940278 IMPEL NEUROPHARMA Nozzles for nasal drug delivery
Jan, 2033

(9 years from now)

US9919117 IMPEL NEUROPHARMA Nozzles for nasal drug delivery
Mar, 2033

(9 years from now)

US11266799 IMPEL NEUROPHARMA In-line nasal delivery device
Nov, 2036

(13 years from now)

US11185497 IMPEL NEUROPHARMA Intranasal delivery of dihydroergotamine by precision olfactory device
Jan, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Sep 2, 2024

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Market Authorisation Date: 02 September, 2021

Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura


More Information on Dosage

TRUDHESA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic